{"id":"fluorouracil-0-5","safety":{"commonSideEffects":[{"rate":null,"effect":"Local irritation, erythema, and inflammation at application site"},{"rate":null,"effect":"Photosensitivity"},{"rate":null,"effect":"Burning and stinging sensation"},{"rate":null,"effect":"Hyperpigmentation or hypopigmentation"}]},"_chembl":{"chemblId":"CHEMBL185","moleculeType":"Small molecule","molecularWeight":"130.08"},"_dailymed":{"setId":"37dcfb83-0e7d-d23d-9cd5-afa5bdc30628","title":"FLUOROURACIL (FLUOROURACIL CREAM, 0.5%) CREAM [DR. REDDY'S LABORATORIES INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluorouracil (5-FU) is converted intracellularly to active metabolites that inhibit thymidylate synthase, blocking dTMP synthesis and thus DNA replication. It also incorporates into RNA, disrupting protein synthesis. The 0.5% topical formulation is used for localized skin lesions where it exerts cytotoxic effects on rapidly dividing cells.","oneSentence":"Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and gets incorporated into RNA and DNA, disrupting nucleotide synthesis and cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:30:35.634Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Actinic keratosis (topical 0.5%)"},{"name":"Superficial basal cell carcinoma (topical)"}]},"trialDetails":[{"nctId":"NCT07398807","phase":"EARLY_PHASE1","title":"Effectiveness of Micro-needling With 5 Fluorouracil Versus Potent Topical Steroids in the Treatment of Limited Vitiligo","status":"RECRUITING","sponsor":"Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan","startDate":"2025-08-08","conditions":"Vitiligo","enrollment":40},{"nctId":"NCT06362226","phase":"PHASE1","title":"Optimizing Ocular Outcomes: A Dual-armed Study for Periorbital Burn Management","status":"NOT_YET_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2026-02-28","conditions":"Periorbital Burns","enrollment":10},{"nctId":"NCT05381597","phase":"PHASE2, PHASE3","title":"5-Fluorouracil and Calcipotriene for Treatment of Low Grade Skin Cancer","status":"RECRUITING","sponsor":"Boston University","startDate":"2022-10-15","conditions":"Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ","enrollment":200},{"nctId":"NCT03044587","phase":"PHASE2","title":"Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-01-24","conditions":"Adenocarcinoma Metastatic, Biliary Tract Cancer, Adenocarcinoma of the Biliary Tract","enrollment":93},{"nctId":"NCT06135896","phase":"PHASE2","title":"Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2024-01-16","conditions":"Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Unresectable Biliary Tract Carcinoma","enrollment":98},{"nctId":"NCT06987123","phase":"PHASE2","title":"TC as Adjuvant Therapy After Surgery for Locally Recurrent Resectable Nasopharyngeal Carcinoma: a Single-arm Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-05-18","conditions":"Nasopharyngeal Carcinoma (NPC)","enrollment":62},{"nctId":"NCT05848739","phase":"PHASE1","title":"A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Sapience Therapeutics","startDate":"2023-06-05","conditions":"Colon Cancer, Metastatic Colon Cancer","enrollment":130},{"nctId":"NCT03468335","phase":"PHASE3","title":"2nd-line Therapy With Nal-IRI After Gem/Nab-pac in Advanced Pancreatic Cancer - Predictive Role of 1st-line Therapy","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2018-03-31","conditions":"Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":151},{"nctId":"NCT06712381","phase":"PHASE1, PHASE2","title":"Carac & PDT Combination in the Treatment Of Actinic Keratoses","status":"COMPLETED","sponsor":"Skin Laser & Surgery Specialists","startDate":"2008-08","conditions":"Actinic Keratoses","enrollment":60},{"nctId":"NCT00838578","phase":"PHASE1, PHASE2","title":"Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-03","conditions":"Colorectal Cancer","enrollment":65},{"nctId":"NCT03376659","phase":"PHASE1, PHASE2","title":"Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2018-08-08","conditions":"Metastatic Colorectal Cancer, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":8},{"nctId":"NCT01740648","phase":"PHASE1","title":"Trametinib, Fluorouracil, and Radiation Therapy Before Surgery in Treating Patients With Stage II-III Rectal Cancer","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2012-11-26","conditions":"Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer","enrollment":19},{"nctId":"NCT05513924","phase":"PHASE2, PHASE3","title":"Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo.","status":"COMPLETED","sponsor":"South Valley University","startDate":"2022-03-15","conditions":"Vitiligo","enrollment":40},{"nctId":"NCT02333188","phase":"PHASE1","title":"Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-12","conditions":"Adenocarcinoma of Unknown Primary, Adult Cholangiocarcinoma, Gallbladder Carcinoma","enrollment":50},{"nctId":"NCT03043547","phase":"PHASE2","title":"Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2017-10-24","conditions":"Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic, Cholangiocarcinoma of the Gallbladder","enrollment":100},{"nctId":"NCT01670409","phase":"PHASE2","title":"Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal Cancer","status":"COMPLETED","sponsor":"Chuangzhen Chen","startDate":"2012-08","conditions":"Esophageal Neoplasms","enrollment":85},{"nctId":"NCT01750918","phase":"PHASE1, PHASE2","title":"BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-12-19","conditions":"Cancer","enrollment":166},{"nctId":"NCT05057663","phase":"NA","title":"Intralesional Treatment of Plantar Wart","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2021-11-01","conditions":"Plantar Wart","enrollment":40},{"nctId":"NCT01369433","phase":"NA","title":"A Rollover Protocol to Allow Continued Access to Tivozanib (AV 951) for Subjects Enrolled in Other Tivozanib Protocols","status":"TERMINATED","sponsor":"AVEO Pharmaceuticals, Inc.","startDate":"2010-06","conditions":"Solid Tumors","enrollment":225},{"nctId":"NCT03023436","phase":"PHASE3","title":"Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-01","conditions":"Stomach Neoplasm","enrollment":220},{"nctId":"NCT02616601","phase":"PHASE3","title":"Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2015-02-27","conditions":"Actinic Keratosis","enrollment":422},{"nctId":"NCT00696488","phase":"PHASE4","title":"Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2007-04","conditions":"Actinic Keratosis","enrollment":20},{"nctId":"NCT03037541","phase":"PHASE3","title":"Cryosurgery and Cream Combination for Actinic Keratosis","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2011-01-05","conditions":"Actinic Keratosis","enrollment":60},{"nctId":"NCT01705002","phase":"PHASE1","title":"Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors.","status":"COMPLETED","sponsor":"Lipomedix Pharmaceuticals Inc.","startDate":"2012-10","conditions":"Cancer, Solid Tumor, Metastatic Colorectal Cancer (mCRC)","enrollment":88},{"nctId":"NCT01467115","phase":"PHASE2","title":"Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer","status":"COMPLETED","sponsor":"Drexel University College of Medicine","startDate":"2010-03","conditions":"Head and Neck Cancer","enrollment":1},{"nctId":"NCT02289768","phase":"PHASE3","title":"Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic Keratoses","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2014-10","conditions":"Actinic Keratosis","enrollment":166},{"nctId":"NCT01354717","phase":"PHASE3","title":"Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo","status":"COMPLETED","sponsor":"Spear Pharmaceuticals","startDate":"2010-09","conditions":"Actinic Keratoses","enrollment":377},{"nctId":"NCT02133014","phase":"NA","title":"The Study of Laparoscopic-assisted Percutaneous Catheter-directed Drainage to Treat Early Severe Acute Pancreatitis","status":"UNKNOWN","sponsor":"Zhujiang Hospital","startDate":"2014-04","conditions":"Pancreatitis, Acute Necrotizing","enrollment":60},{"nctId":"NCT00377273","phase":"PHASE4","title":"An Open-Label 18-Month Safety Study of Fluorouracil Cream 0.5% for the Treatment of Actinic Keratoses","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Actinic Keratoses","enrollment":250}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Carac"],"phase":"marketed","status":"active","brandName":"Fluorouracil 0.5%","genericName":"Fluorouracil 0.5%","companyName":"Wake Forest University","companyId":"wake-forest-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluorouracil 0.5% is a small molecule inhibitor of thymidylate synthase, a class of INHIBITOR drugs. It is used to treat various conditions, including Esophageal Neoplasms, Head and Neck Cancer, Actinic Keratoses, Cancer, and Solid Tumors, often in combination with other treatments such as radiotherapy and chemotherapy.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}